Core Viewpoint - Fractyl Health, Inc. is calling all outstanding Tranche A Warrants for cancellation or exercise, with a deadline of December 30, 2025, potentially raising up to $17.9 million in gross proceeds if all warrants are exercised [1][6]. Group 1: Tranche A Warrants Details - Holders of Tranche A Warrants can exercise them at an exercise price of $1.05 per share until the Cancellation Date [2]. - As of the announcement, there are approximately 17,063,073 Tranche A Warrants outstanding, with the last reported sale price of the Common Stock at $2.24 per share, indicating a premium of $1.19 over the exercise price [3]. - Any unexercised Tranche A Warrants after the Cancellation Date will be void and holders will receive $0.00001 per share [5]. Group 2: Conditions for Calling Warrants - The call of the Tranche A Warrants was enabled after the company met clinical and market performance conditions, including positive data from the REMAIN-1 study and trading conditions where the Common Stock exceeded an average closing price of $1.37 for 15 consecutive trading days [4]. Group 3: Financial Implications - If all outstanding Tranche A Warrants are exercised, Fractyl will receive approximately $17.9 million in additional gross proceeds, which will strengthen the company's balance sheet as it advances its clinical programs [6]. Group 4: Company Overview - Fractyl Health is focused on pioneering new approaches to treat metabolic diseases, including obesity and type 2 diabetes, aiming to transform treatment from chronic management to disease-modifying therapies [10][11]. - The company has a robust intellectual property portfolio with 35 granted U.S. patents and around 45 pending applications [11].